Experimental Placental Cell Therapy Now Available to Florida Patients Outside FDA Approval
Celularity and Fountain Life are offering an investigational cell therapy in Florida under a new state law bypassing FDA approval.
Summary
Celularity and Fountain Life are now offering Cenplacel-L, an experimental placental-derived cell therapy, to patients in Florida through a legal pathway that allows physicians to use certain unapproved therapies under state law effective July 2025. The therapy, also known as PDA-001 or PDA-002 in clinical research, targets inflammation, tissue degeneration, and age-related disease, with potential uses in wound care and orthopedics. It is manufactured at an FDA-registered, GMP-compliant facility but has not received FDA approval. The partnership frames this as a preventive longevity care model combining advanced diagnostics, careful patient selection, and physician oversight. Data gathered may help shape future development strategies.
Detailed Summary
Celularity and Fountain Life have announced the availability of Cenplacel-L, an investigational placental-derived allogeneic cell therapy, for physician-directed use in Florida starting July 1, 2025. This is made possible by recently enacted Florida state statutes that permit licensed physicians to administer certain cell therapies that have not yet received FDA approval. The announcement marks a significant moment at the intersection of regenerative medicine, longevity care, and evolving state-level healthcare regulation.
Cenplacel-L, known in clinical research as PDA-001 or PDA-002, is Celularity's lead asset in its off-the-shelf cell therapy platform. The therapy is derived from placental tissue and is designed to address inflammation, tissue degeneration, and age-related disease processes. Target applications include wound care and orthopedics, with broader longevity implications tied to its anti-inflammatory and regenerative mechanisms. The therapy is stored at an FDA-registered, GMP-compliant manufacturing facility, ensuring a degree of production quality control.
The partnership with Fountain Life — a preventive health and longevity clinic network — positions Cenplacel-L within a broader diagnostics-driven care model. Patient selection, advanced biomarker testing, and physician oversight are described as central to the program, suggesting a more rigorous approach than typical unregulated wellness offerings. The companies say real-world data from this channel will inform clinical development strategies and best practices.
For longevity-focused individuals, this represents early access to a regenerative therapy with promising biological rationale, but important caveats apply. Cenplacel-L has not been FDA-approved, meaning its efficacy and safety have not been validated through the standard regulatory process. Florida's legal framework creates a novel but legally distinct pathway that does not substitute for peer-reviewed clinical trial evidence.
Health-conscious consumers and physicians should approach this with cautious curiosity. The therapy may offer genuine benefit, but independent clinical data remains limited, and the regulatory workaround deserves scrutiny before widespread adoption.
Key Findings
- Cenplacel-L is now available to Florida patients via a state law allowing physician-directed use of unapproved cell therapies.
- The therapy targets inflammation, tissue degeneration, and age-related disease using placental-derived allogeneic cells.
- Fountain Life will integrate advanced diagnostics and patient selection into the treatment model for oversight.
- The therapy is manufactured at a GMP-compliant facility but lacks FDA approval — a critical distinction for safety assessment.
- Real-world use data is intended to guide future clinical development strategies for Celularity.
Methodology
This is a news report based on a corporate press announcement from Celularity and Fountain Life. The source, Longevity.Technology, is a specialist publication covering the longevity sector with generally credible industry reporting. No independent clinical trial data or peer-reviewed evidence is cited to support the therapy's efficacy claims.
Study Limitations
Cenplacel-L has not received FDA approval, meaning its safety and efficacy have not been independently validated through rigorous regulatory review. The announcement is based on a corporate press release, not peer-reviewed research, so efficacy claims should be verified against published clinical data. Patients and physicians should assess the legal and medical implications of Florida's state statute pathway carefully before proceeding.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.